HK inno.N Corporation (KOSDAQ:195940)

South Korea · Delayed Price · Currency is KRW

42,800

+4,650 (12.19%)

Jun 29, 2026, 3:30 PM KST

1.18% (1Y)

Market Cap	1.21T +2.9%
Revenue (ttm)	839.63B +12.9%
Net Income	41.49B +58.1%
EPS	1,451.65 +96.5%
Shares Out	28.33M
PE Ratio	29.48
Forward PE	12.41
Dividend	350.00 (0.92%)
Ex-Dividend Date	Mar 30, 2026

Volume	238,326
Open	38,500
Previous Close	38,150
Day's Range	38,500 - 42,850
52-Week Range	37,300 - 58,600
Beta	0.52
Analysts	Buy
Price Target	68,636.36 (+60.37%)
Earnings Date	Jul 28, 2026

About HK inno.N

HK inno.N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, no... [Read more]

Industry Medical Care Facilities

Sector Healthcare

Founded 1984

Employees 1,695

Stock Exchange KOSDAQ

Ticker Symbol 195940

Full Company Profile

Financial Performance

In 2021, HK inno.N's revenue was 769.79 billion, an increase of 28.63% compared to the previous year's 598.45 billion. Earnings were 21.35 billion, a decrease of -23.49%.

Financial Statements

Analyst Summary

According to 11 analysts, the average rating for 195940 stock is "Buy." The 12-month stock price target is ₩68,636, which is an increase of 60.37% from the latest price.

Price Target

₩68,636

(60.37% upside)

Analyst Consensus: Buy

Stock Forecasts